Collaboration - June 5, 2015
Biogen Files MAA for Hemophilia Drug
Swedish Orphan Biovitrum AB (Sobi’s) partner Biogen has submitted a Marketing Authorisation Application (MAA) for Alprolix (rFIXFc) to the European Medicines Agency (EMA). Sobi has an opt-in right to assume final development and commercialization of Alprolix in Europe, Russia, certain countries in the Middle East, and North Africa, according to Sobi. The MAA filing with […]
Collaboration - June 4, 2015
AZ Might Consider CAR-T Firm
After AstraZeneca told Bloomberg it might be interested in a cancer therapy company, Juno Therapeutics’ stocks jumped by more than 15.3 percent this week, according to BioSpace.com. AstraZeneca’s CEO Pascal Soriot made the comments after he was asked whether his firm would be interested in a company like Juno, which develops ways the body can use its […]
Collaboration - May 29, 2015
Poultry Probiotic in Works
Adisseo and Novozymes have formed a partnership to develop and market a probiotic for poultry. Novozymes will be responsible for in-vitro screening, development and production, while Adisseo will manage in-vivo testing, marketing and sales. The partners expect to launch the product within the next 12 months, according to BioSpace.com. “The world needs new solutions to […]
Collaboration - May 27, 2015
Amgen, AZ End Psoriasis Drug Deal
Amgen is dissolving an agreement with AstraZeneca to develop the psoriasis drug brodalumab after a patient involved in a late-stage trial developed suicidal thoughts and behavior, according to BioSpace.com. Because of that incident, if the drug were eventually approved by regulators, they would likely require restrictive labeling, which discouraged Amgen. The latest news came as […]
Collaboration - May 11, 2015
Recipharm, LIDDS Talk Collaboration
Recipharm has begun negotiations with the pharmaceutical company LIDDS about collaborating on making Liproca Depot® ahead of continued clinical development and a potential future market launch. The companies explained in a joint letter their intention to initiate collaboration in the areas of scale-up, manufacture and quality assurance of LIDDS’ pharmaceutical products. Initially the companies will […]
Collaboration - May 11, 2015
Biobank Could Help Diamyd with Diabetes Vaccine
Diamyd, which is developing a vaccine against type 1 diabetes, now owns 39 percent of Cellaviva, Sweden’s first commercial biobank for stem cells. Diamyd made the investment because of the potential resource for research. “We believe in stem cells. Among other things, we hope that in the future we will be able to use them […]
